IgAN
Advertisement
Research identified the optimal biomarker combination to predict interstitial fibrosis surface in IgA nephropathy.
Long-term data demonstrated that zigakibart reduced proteinuria and stabilized kidney function of patients with IgAN.
Moderate-to-severe chronic arteriolar lesions were found to be independent risk factors for adverse renal prognosis in IgAN.
A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.
Several genetically predicted environmental factors increase the risk of IgAN and membranous nephropathy, a study found.
An analysis Identified SIRT1, BAG3, COKN1A and FOS as potential autophagy-related biomarkers for IgAN.
Research identified microRNA-483-5p as a possible biomarker for IgA nephropathy to help with risk stratification.
The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy.
We spoke with ALIGN study investigator Richard Lafayette, MD, upon the FDA's accelerated approval of atrasentan for IgAN.
Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgAN.
One-year results of the AFFINITY trial of atrasentan to treat proteinuria among patients with IgAN were presented at SCM25.
Researchers shared baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy.
Otsuka filed a Biologics License Application with the FDA for sibeprenlimab for the treatment of IgA nephropathy (IgAN).
The Freely Filtered Filtrate discusses the top nephrology stories of 2024, including FLOW, cyberattacks, and IgAN trials.
SC0062 met the 12-week primary end point of a reduction in proteinuria in a study cohort with diabetic kidney disease (DKD).
A systematic evaluation compared the incidence of IgAN and changes in its pathology before and during the COVID-19 pandemic.
Researchers wanted to understand kidney changes with O. felineus infection and whether there is an association with IgAN.
Interim APPLAUSE-IgAN data showed that iptacopan was superior to placebo at reducing proteinuria at nine months.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.